2026-09-26T02:39:14Zhttps://dspace.mit.edu/server/oai/request

oai:dspace.mit.edu:1721.1/626722026-06-06T01:04:09Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023

Stanley B. Gershwin. Liow, Yuh Han John Massachusetts Institute of Technology. Dept. of Mechanical Engineering. Massachusetts Institute of Technology. Department of Mechanical Engineering 2011-05-09T15:17:38Z 2011-05-09T15:17:38Z 2010 2010 http://hdl.handle.net/1721.1/62672 714254959 Thesis (M. Eng. in Manufacturing)--Massachusetts Institute of Technology, Dept. of Mechanical Engineering, 2010. Cataloged from PDF version of thesis. Includes bibliographical references (p. 57). The manufacturing production of active pharmaceutical ingredients often involve a series of processing stages in which yield limits are prescribed to ensure that the target yield has been achieved for a batch and that the workers may proceed to the next batch of materials. Such yield limits is comprised of a maximum value for yields above 100% and a minimum value for yields of lower than 100%. These yield limits for each of the processing steps are conventionally prescribed based on accumulated experiences with production after an extended period of time. This paper is based on an internship project at a major pharmaceutical firm in Singapore, and it discusses the sources of yield losses and the reasons behind yield excursions which have not been well documented within the production facility. In doing so, the paper attempts to provide insights into the possible explanations for the current maximum and minimum yield limits application. Furthermore, using the yield limit values as applied for certain products, a preliminary framework is developed to provide a set of recommendations for the adjustment of conventional yield limit values to suit similar processing stages for the manufacturing of a novel drug product. This framework should prove to be useful in meeting the uncertainties inherent in the production of new products and in making initial recommendations for yield limits since there is usually limited experience from drug developments and clinical manufacture. by Yuh Han John, Liow. M.Eng. in Manufacturing 57 p. eng Massachusetts Institute of Technology M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission. http://dspace.mit.edu/handle/1721.1/7582 Mechanical Engineering. Framework for the determination of yield limits In pharmaceutical operations Thesis application/pdf Publication unknown unknown <Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="f99f68ca-1e88-4dd2-8639-a4c0a07ceeed"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>Framework for the determination of yield limits In pharmaceutical operations</Title> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2010</PublicationDate> <Authors> <Author> <DisplayName>Liow, Yuh Han John</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Massachusetts Institute of Technology</DisplayName> <OrgUnit /> </Publisher> </Publishers> <License>http://dspace.mit.edu/handle/1721.1/7582</License> <Keyword>Mechanical Engineering.</Keyword> <Abstract>The manufacturing production of active pharmaceutical ingredients often involve a series of processing stages in which yield limits are prescribed to ensure that the target yield has been achieved for a batch and that the workers may proceed to the next batch of materials. Such yield limits is comprised of a maximum value for yields above 100% and a minimum value for yields of lower than 100%. These yield limits for each of the processing steps are conventionally prescribed based on accumulated experiences with production after an extended period of time. This paper is based on an internship project at a major pharmaceutical firm in Singapore, and it discusses the sources of yield losses and the reasons behind yield excursions which have not been well documented within the production facility. In doing so, the paper attempts to provide insights into the possible explanations for the current maximum and minimum yield limits application. Furthermore, using the yield limit values as applied for certain products, a preliminary framework is developed to provide a set of recommendations for the adjustment of conventional yield limit values to suit similar processing stages for the manufacturing of a novel drug product. This framework should prove to be useful in meeting the uncertainties inherent in the production of new products and in making initial recommendations for yield limits since there is usually limited experience from drug developments and clinical manufacture.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication>